Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular DegenerationDaniel Martín, Frederick L. Ferris, Maureen G. Maguire et al.|Ophthalmology|2012Cited by 1.7k
Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular DegenerationMaureen G. Maguire, Stuart L. Fine, Daniel Martín et al.|Ophthalmology|2016Cited by 702
Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments TrialsJuan E. Grunwald, Daniel Martín, Barbara Blodi et al.|Ophthalmology|2013Cited by 585
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments TrialsEbenezer Daniel, Maureen G. Maguire, Cynthia A. Toth et al.|Ophthalmology|2013Cited by 325
Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular DegenerationGui‐Shuang Ying, Daniel Martín, Jiayan Huang et al.|Ophthalmology|2012Cited by 310